Human Health

Forbion Ventures

Forbion Ventures builds, invests and supports breakthrough innovation.

Person standing on a mountain with mist surrounding

Forbion Ventures Fund (Forbion Funds III, IV, V, VI) builds, invests and supports innovative companies with a prime focus on Europe. Most of these concentrate on pre-clinical to early clinical stage companies.

Building Companies
Companies that we build make up about one third of the Ventures portfolio. These companies are often created together with proven entrepreneurs and teams surrounded by novel and in-licensed assets.

Supporting & Enabling Companies
Selected from more than 1,400 deals, we support and enable companies to grow and accelerate to value inflection points. Two thirds of the Ventures fund consist of companies with this profile.

Portfolio

€460m

Forbion Ventures V closed in December 2020

€750m

Forbion Ventures Fund VI closed in April 2023

€900m

Forbion Ventures Fund VII closed in October 2024

Funds

Forbion Fund III

Forbion Fund IV

Forbion Fund V

Forbion Fund VI

Forbion Fund VII

Forbion announces the final closing of its third main fund Forbion Capital Fund III (FCF III).

Forbion closed its oversubscribed fourth flagship fund, Forbion IV at €360M in October 2018. The fund seeks to build and support EU and US biopharma companies by combining new ventures with existing opportunities, targeting transformative drugs, proven teams, and impactful financial and societal returns.

On December 8, 2020, Forbion announced the €460M close of its oversubscribed fifth flagship fund, Forbion V, launched in October, to invest in 15 innovative therapeutics companies across Europe and North America.

Forbion Ventures Fund VI closed at €750m in April 2023.

Forbion Ventures Fund VII closed at €890m in October 2024 and builds a portfolio of innovative therapeutics-focused biotechs, both existing companies as well as NewCos, (co-) founded by Forbion, created around assets sourced from pharma or academic institutions, or around proven management teams.

Funds

The steady and sustained growth of our funds over the years reflects the strong confidence our investors have in Forbion’s stability and long-term vision.

This consistent performance underscores our disciplined investment approach, deep industry expertise, and commitment to building lasting value in the life sciences sector.